Clinical Trial Update: A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL [Phase 2]

View source ↗

Summary

Phase 2 trial update for ICP-022 in patients with relapsed/refractory primary CNS lymphoma and secondary CNS lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• ICP-022

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: PCNSL, Secondary Central Nervous System Lymphoma | Phase 2 | Status: UNKNOWN